GLP Watchdog

Major trials

SELECT

The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.

Definition

Cardiovascular outcomes for semaglutide 2.4 mg in 17,604 adults with overweight or obesity and established CV disease, without diabetes (Lincoff et al., NEJM 2023). Major adverse cardiovascular events fell 20% (HR 0.80, 95% CI 0.72–0.90). It is why this drug is now discussed as cardiac prevention rather than cosmetics.

SELECT trial cardiovascular benefits →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under Major trials

Where the evidence lives